NCT06723080
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Chinese Academy of Medical Sciences Hospital for Skin Diseases Nanjing, Jiangsu, China
Clinical trial condition
Moderate to Severe Atopic Dermatitis
Explore clinical trials studying Moderate to Severe Atopic Dermatitis. Study availability and eligibility vary by location and protocol.
15 public trials
3 recruiting studies
Moderate to Severe Atopic Dermatitis trial results
NCT07558668
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Sitryx Clinical Site Arkansas City, Arkansas, United States
- Sitryx Clinical Site Fremont, California, United States
- Sitryx Clinical Site Plainfield, Indiana, United States
- Sitryx Clinical Site Boardman, Ohio, United States
NCT06239311
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- MU Dr. Petr Arenberger, DrSc. MBA Prague, Praha 1, Czechia
- Synexus Czech s.r.o. Prague, Praha 2, Czechia
- Praglandia s.r.o. Prague, Praha 5, Czechia
- AGE Centrum s.r.o. Olomouc, Czechia
NCT07465120
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Beijing Huairou Hospital Beijing, Beijing Municipality, China
- Beijing Tongren Hospital, Capital Medical University Beijing, Beijing Municipality, China
- China-Japan Friendship Hospital Beijing, Beijing Municipality, China
- First Affiliated Hospital of Fujian Medical University Fuzhou, Fujian, China
Not yet recruiting
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
NCT07370909
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Peking University People's Hospital Beijing, China
Active, not recruiting
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Nektar Investigative Site Bryant, Arkansas, United States
- Nektar Investigative Site Fountain Valley, California, United States
- Nektar Investigative Site Los Angeles, California, United States
- Nektar Investigative Site Los Angeles, California, United States
Active, not recruiting
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
NCT06468956
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Shanghai Fudan University HuaShan Hospital Shanghai, Shanghai Municipality, China
NCT05197023
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Peking University Third Hospital Beijing, Beijing Municipality, China
NCT06099704
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Investigational Site Number : 1240019 Calgary, Alberta, Canada
- Investigational Site Number : 1240021 Calgary, Alberta, Canada
- Investigational Site Number : 1240009 Edmonton, Alberta, Canada
- Investigational Site Number : 1240007 Edmonton, Alberta, Canada
Completed
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
NCT05549947
- Conditions
- Moderate to Severe Atopic Dermatitis
- Locations
-
- Huashan Sub-Hospital of Fudan University Shanghai, Shanghai Municipality, China